CLINICAL TRIAL

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-03-11
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Yale University

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction OCD Receptor Pharmacology Clinical Trial Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.Journal of clinical psychopharmacology · 2026-01-01 Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026-06-02 Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15 Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.Journal of psychopharmacology (Oxford, England) · 2026-01-01 Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01 Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-28 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorderJournal of Psychopharmacology · 2026-05-01